Patents by Inventor Scott M. Herbig

Scott M. Herbig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6706283
    Abstract: Controlled release dosage forms for low solubility drugs are disclosed wherein an amorphous solid dispersion of the drug is coated with a non-dissolving and non-eroding coating that controls the influx of water to the core so as to cause extrusion of a portion of the core, as well as a method of treating a disease or disorder comprising administering such dosage form to a person.
    Type: Grant
    Filed: January 31, 2000
    Date of Patent: March 16, 2004
    Assignee: Pfizer Inc
    Inventors: Leah E. Appel, William J. Curatolo, Scott M. Herbig, James A. S. Nightingale, Avinash G. Thombre
  • Publication number: 20030219489
    Abstract: Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or biavailability in a use environment.
    Type: Application
    Filed: June 9, 2003
    Publication date: November 27, 2003
    Applicant: Pfizer Inc.
    Inventors: William J. Curatolo, Scott M. Herbig, James A. S. Nightingale
  • Patent number: 6641840
    Abstract: The present invention relates to formulations for administering a growth hormone secretagogue. More specifically, the present invention relates to sustained release formulations for administering a growth hormone secretagogue and formulations for administering a growth hormone secretagogue that provide for a part of the dose of the growth hormone secretagogue to be administered using an immediate release formulation and part of the dose of the growth hormone secretagogue to be administered using a sustained release formulation.
    Type: Grant
    Filed: August 27, 2001
    Date of Patent: November 4, 2003
    Assignee: Pfizer Inc.
    Inventors: Mary T. Am Ende, William J. Curatolo, Scott M. Herbig
  • Publication number: 20030086972
    Abstract: A controlled release dosage form has a coated core with the core comprising a drug-containing composition and a water-swellable composition, each occupying separate regions within the core. The coating around the core is water-permeable, water-insoluble and has at least one delivery port therethrough. A variety of geometric arrangements are disclosed.
    Type: Application
    Filed: August 1, 2001
    Publication date: May 8, 2003
    Inventors: Leah E. Appel, Walter C. Babcock, Ronald A. Beyerinck, Mark B. Chidlaw, William J. Curatolo, Dwayne T. Friesen, Scott M. Herbig, Avinash G. Thombre
  • Publication number: 20020137765
    Abstract: The present invention relates to formulations for administering a growth hormone secretagogue. More specifically, the present invention relates to sustained release formulations for administering a growth hormone secretagogue and formulations for administering a growth hormone secretagogue that provide for a part of the dose of the growth hormone secretagogue to be administered using an immediate release formulation and part of the dose of the growth hormone secretagogue to be administered using a sustained release formulation.
    Type: Application
    Filed: August 27, 2001
    Publication date: September 26, 2002
    Inventors: Mary T. Am Ende, William J. Curatolo, Scott M. Herbig
  • Publication number: 20020009494
    Abstract: Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or biavailability in a use environment.
    Type: Application
    Filed: January 26, 2001
    Publication date: January 24, 2002
    Inventors: William J. Curatolo, Scott M. Herbig, James A.S. Nightingale
  • Patent number: 5827538
    Abstract: An osmotic device that, following the imbibement of water vapor, provides for the controlled release of a beneficial agent to an aqueous environment. The device comprises a hydrophilic formulation including a beneficial agent, and if needed, an osmagent, surrounded by a wall. The wall is formed at least in part of a semipermeable hydrophobic membrane having an average pore size between about 0.1 .mu.m and 30 .mu.m. The pores are substantially filled with a gas phase. The hydrophobic membrane is permeable to water in the vapor phase and the hydrophobic membrane is impermeable to an aqueous medium at a pressure less than about 100 Pa. The beneficial agent is released, for example, by osmotic pumping or osmotic bursting upon imbibement of sufficient water vapor into the device core.
    Type: Grant
    Filed: January 17, 1996
    Date of Patent: October 27, 1998
    Assignee: Pfizer Inc.
    Inventors: Edward L. Cussler, Scott M. Herbig, Kelly L. Smith, Paul van Eikeren
  • Patent number: 5798119
    Abstract: An osmotic device that, following the imbibition water vapor, provides for the controlled release of a beneficial agent to a non-aqueous environment. The device comprises a hydrophilic formulation and a beneficial agent, surrounded by a wall. The wall is formed at least in part of a semipermeable hydrophobic microporous membrane having an average pores size between about 0.1 .mu.m and 30 .mu.m. The pores are substantially filled with a gas phase. The hydrophobic membrane is permeable to water in the vapor phase and the hydrophobic membrane is impermeable to an aqueous medium at a pressure less than about 100 Pa. The beneficial agent is released, for example, by osmotic pumping or osmotic bursting upon imbibition of sufficient water vapor into the hydrophilic formulation. The high water fluxes attendant with these vapor-permeable hydrophobic membranes facilitate the delivery of large quantities of beneficial agents without requiring large surface areas (quantities) of hydrophobic microporous membrane.
    Type: Grant
    Filed: June 13, 1995
    Date of Patent: August 25, 1998
    Assignee: S. C. Johnson & Son, Inc.
    Inventors: Scott M. Herbig, Eric J. Miller
  • Patent number: 5698220
    Abstract: A device for controlled release of an active substance through one or more asymmetric membranes by diffusion and/or osmotic pumping.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 16, 1997
    Assignee: Pfizer Inc.
    Inventors: John R. Cardinal, Scott M. Herbig, Richard W. Korsmeyer, Jeelin Lo, Kelly L. Smith, Avinash G. Thombre
  • Patent number: 5612059
    Abstract: A device for controlled release of an active substance through one or more asymmetric membranes by diffusion and/or osmotic pumping.
    Type: Grant
    Filed: September 25, 1992
    Date of Patent: March 18, 1997
    Assignee: Pfizer Inc.
    Inventors: John R. Cardinal, Scott M. Herbig, Richard W. Korsmeyer, Jeelin Lo, Kelly L. Smith, Avinash G. Thombre
  • Patent number: 5609590
    Abstract: An osmotic bursting device for dispensing a beneficial agent to an aqueous environment. The device comprises a beneficial agent and osmagent surrounded at least in part by a semipermeable membrane. Alternatively the beneficial agent may also function as the osmagent. The semipermeable membrane is permeable to water and substantially impermeable to the beneficial agent and osmagent. A trigger means is attached to the semipermeable membrane (e.g., joins two capsule halves). The trigger means is activated by a pH of from 3 to 9 and triggers the eventual, but sudden, delivery of the beneficial agent. These devices enable the pH-triggered release of the beneficial agent core as a bolus by osmotic bursting.
    Type: Grant
    Filed: October 19, 1994
    Date of Patent: March 11, 1997
    Assignee: Pfizer Inc.
    Inventors: Scott M. Herbig, Kelly L. Smith
  • Patent number: 5603953
    Abstract: Supported liquid membrane delivery devices that release a beneficial agent to an aqueous environment following exposure to an environmental trigger. A microporous hydrophobic support membrane at least partially surrounds a beneficial agent- containing hydrophilic formulation. A hydrophobic liquid is held within the microporous support membrane by capillarity and the hydrophobic liquid is substantially permeable to the aqueous environment and the beneficial agent-containing hydrophilic formulation. The entrained hydrophobic liquid becomes substantially permeable to the aqueous environment upon exposure to an environmental trigger such as an enzyme, and the beneficial agent is subsequently released.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: February 18, 1997
    Assignee: Pfizer Inc.
    Inventors: Scott M. Herbig, Kelly L. Smith, Paul Van Eikeren, James B. West
  • Patent number: 5358502
    Abstract: An osmotic bursting device for dispensing a beneficial agent to an aqueous environment. The device comprises a beneficial agent and osmagent surrounded at least in part by a semipermeable membrane. Alternatively the beneficial agent may also function as the osmagent. The semipermeable membrane is permeable to water and substantially impermeable to the beneficial agent and osmagent. A trigger means is attached to the semipermeable membrane (e.g., joins two capsule halves). The trigger means is activated by a pH of from 3 to 9 and triggers the eventual, but sudden, delivery of the beneficial agent. These devices enable the pH-triggered release of the beneficial agent core as a bolus by osmotic bursting.
    Type: Grant
    Filed: February 25, 1993
    Date of Patent: October 25, 1994
    Assignee: Pfizer Inc
    Inventors: Scott M. Herbig, Kelly L. Smith
  • Patent number: 5091080
    Abstract: Semipermeable membrane-enclosed solid core adsorbent devices for the selective removal of volatile chemical species from an aqueous environment are disclosed.
    Type: Grant
    Filed: November 30, 1990
    Date of Patent: February 25, 1992
    Assignee: Bend Research, Inc.
    Inventors: Paul van Eikeren, Daniel J. Brose, Scott M. Herbig